LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 10th, 2022 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is entered into as of January 9, 2022 (the “Effective Date”), by and between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (“Stoke”), and Acadia Pharmaceuticals Inc. a Delaware corporation having offices at 12830 El Camino Real, Suite 400 San Diego, CA 92130 (“Acadia”). Stoke and Acadia are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
